Prolonging Treatment Response in Follicular Lymphoma
Post-induction consolidation therapy with 90Y-ibritumomab tiuxetan radioimmunotherapy prolonged progression-free survival in patients with advanced-stage follicular lymphoma.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)